Amgen Completes Acquisition of Ilypsa, Inc.
Published: Jul 19, 2007
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) announced today the completion of its acquisition of Ilypsa, a private company developing non-absorbed drugs for renal disorders. The transaction provides Amgen with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on hemodialysis. The acquisition was originally announced June 4.